Hebei Senlang Biotechnology

China
Duru, Guizhou, China

Company profile

Hebei Senlang Biotechnology company profile

Hebei Senlang Biotechnology is focused on the treatment of immune cells new technology development and application of high-tech enterprises.The company has the CAR-T research base (Senrang CAR-T Research Center) in North China, and has formed a high-barrier technology platform such as innovative CAR structural design, virus and cell culture , which can take into account technical research and development, hospital clinical application Provide high-quality and effective cellular immunotherapy support for hematological tumors, solid tumors and other tumor diseases, immune system diseases and other patients.

Business identity

Phone number
+86-311-82970975
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$1M-$10M
Founded
2016-01-01, Year

Headquarters

Country code
CN
Continent
Asia

Capital profile

Funding and company signals

Funding stage
Private Equity
Funding rounds
2
Total equity funding
$29.6M
Last funding
Private Equity / $29.6M / 2022-05-18
Last equity funding
Private Equity / $29.6M
Investors
4
Lead investors
1
Founders
1
Articles
9

Founders and investors

Founders

Jianqiang Li

Lead investors

Qianhai Fund of Funds

Investors

Guochuang InvestmentHebei XianchuangMinyin InternationalQianhai Fund of Funds